Professor Christopher Byrne PhD, FRCPath, FRCP

Professor of Endocrinology and Metabolism, Honorary Consultant Diabetologist & Metabolic Physician

Related links

Professor Christopher Byrne is Professor of Endocrinology and Metabolism within Medicine at the University of Southampton.

Christopher Byrne was appointed to the Chair of Endocrinology & Metabolism at the University of Southampton in 1999. He trained at Cardiff, Hammersmith Hospital, Cambridge and Stanford Universities. As an MRC clinical training fellow he undertook his PhD in Cambridge (Downing College 1989-1992). He then undertook a 2 year travelling fellowship at Stanford University, CA and was then an MRC fellow at Cambridge University from 1994-1999. He was inaugural Director of the Wellcome Trust Clinical Research Facility at Southampton and is now Principal Investigator within the NIHR Southampton Biomedical Research Centre. He has published approximately 250 publications and three books related to metabolic syndrome and NAFLD. He is also Consultant Metabolic physician at University Hospital Southampton, where he provides a service focusing on diabetes, obesity and dyslipidaemias. In 2012, he was recipient of the Dorothy Hodgkin prize awarded by Diabetes UK for his research related to diabetes. He is a founder member of the European Association for the Study of Diabetes NAFLD study Group, and is past President of the Royal Society of Medicine, Lipids, Metabolism and Cardiovascular Risk Section.

Achievements

MRC Training Fellow 1990-92
Pfizer Academic Travel Award 1991
Peel Trust Travelling Fellow 1992-93
Cambridge University/Parke Davis Travelling Fellow 1993-94
MRC Fellow 1994-99
Fournier Lipidology Award 1999
British Hyperlipidaemia Association & Parke Davis/Pfizer Award 1999
John French Lectureship 1999
Eli Lilly Award 2000
Membership Association of Physicians 2003
Dorothy Hodgkin Award Diabetes UK 2012
President RSM Lipids, Metabolism and Vascular Risk section (2013 - )

Qualifications

MB BCh University of Wales (medicine honours) (1983),
PhD University of Cambridge (1992), FRCP UK (2000), FRCPath UK (2002)

Appointments held

MRC Training Fellow, University Depts of Clin Biochem & Medicine, Postgraduate student Downing College Cambridge 1989-1992
Senior Registrar Medicine, Addenbrooke’s Hospital 1991-1992
Post Doctoral Research Fellow, Stanford University School of Medicine, Stanford, California USA, 1992-1994
MRC Fellow, Hon Consultant Physician, & Senior Research Associate, Depts of Clinical Biochemistry & Medicine, Addenbrooke’s Hospital, Cambridge 1994-1999
Director Wellcome Trust Clinical Research Facility, Southampton University Hospitals Trust, 4/1999 to 10/2003.

Research

Responsibilities

Publications

Teaching

Contact

Research interests

In 1989, Professor Byrne embarked upon research with the late Professor CN Hales in the University Department of Clinical Biochemistry, Cambridge supported by an MRC Clinical Training Fellowship. The purpose of his PhD thesis was to investigate the effects of insulin and different types of non esterified fatty acids on hepatic lipoprotein secretion in vitro. In 1992 he embarked upon a two year period of study as a Visiting Fellow and post-doctoral scientist at the Falk Cardiovascular Research Center, Stanford University School of Medicine, California, studying the apolipoprotein(a)/plasminogen gene cluster and mapping the gene cluster on chromosome 6 and during that time he identified and characterised two novel apolipoprotein(a)-related genes.

In 1994 he returned to Cambridge supported by an MRC Fellowship to study molecular mechanisms involved in the aetiology of cardio-metabolic risk factors. He completed clinical training and was appointed consultant in metabolic medicine at Addenbrooke’s hospital in 1996. In 1999, Professor Byrne and his research team moved to the University of Southampton.

The research team’s current programme is focussed on the aetiology, pathogenesis, extra-hepatic complications, and testing novel nutritional-based treatments for non alcoholic fatty liver disease.

(see Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015 Apr;62(1S):S47-S64 & Bhatia, L.S., Curzen, N., Calder, P.C. and Byrne, Christopher D. (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor. European Heart Journal, 33, (10), 1190-200.)

Professor Byrne collaborates with national and international colleagues on studies related to NAFLD, metabolic syndrome, and cardiovascular risk factors. (Professor Sarah Wild University of Edinburgh, UK, Professor Ki-Chul Sung from Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Professor Giovanni Targher from the University of Verona, Italy, Professor Michael Boyle from the University of West Indies at Mona in Jamaica and Professor Valerio Nobili from the University of Rome, Italy)

Research project

Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD (non alcoholic fatty liver disease) with OMacor thErapy: WELCOME Study

(www.clinicaltrials.gov registration number NCT00760513)

The WELCOME (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD [non alcoholic fatty liver disease] with OMacor thErapy) study was a phase IV trial that was undertaken in 100 patients with non alcoholic fatty liver disease (NAFLD). The WELCOME study tested the effects of high dose purified n-3 long chain fatty acids (Omacor- Solvay/Abbott/Pronova 4 grames o.d. on a range of liver and cardio-metabolic outcomes. The WELCOME study was run within the Southampton NIHR Biomedical Research Centre in Nutrition, Lifestyle and Obesity. The trial enabled collaborations with another UK BRU, three other UK universities and with industry (Solvay and Pronova). The trial had core funding from NIHR and also attracted extra grant support from Diabetes UK, the NHS and the University of Pavia (Italy). The WELCOME study was registered with the Diabetes and Hepatology networks. The trial was also adopted by the NIHR Portfolio.

Investigation of the effects of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease

Investigation of synbiotic treatment in NAFLD (INSYTE)

www.clinicaltrials.gov registration number NCT01680640

REC: 12/SC/0614

The objective of this study is to determine the effects of altering gut microbiota in patients with NAFLD through administration of a combination of a pre and a probiotic (termed a synbiotic) on liver fat and a range of disease biomarkers. Our specific hypothesis is that: synbiotic treatment is beneficial in decreasing liver fat content and synbiotic treatment favourably changes the gut microbiota composition. Our specific aims are: to test the effects of the synbiotic intervention on the primary outcomes (changes in: liver fat percentage and gut microbiota composition) and secondary outcomes (changes in: liver mitochondrial function, gut permeability, gut hormone profile, serum lipopolysaccharide levels, plasma/faecal short chain fatty acids levels, plasma/urine/faecal bile acid and plasma/urine trimethyl-amine (TMA) concentrations).

Our study will elucidate whether treatment with a synbiotic can modify gut microbiota and decrease liver fat. Additionally, we will test whether synbiotic treatment can modify metaorganismal pathways and improve metabolic and cardiovascular risk factors associated with NAFLD.

Academic unit(s)

Human Development and Health Academic Units

Affiliate academic unit(s)

Human development and physiology Research group

Postgraduate supervision

PhD supervision

Dr Junlong Zhang University of Cambridge 2000
Dr Meis Moukayed University of Cambridge 2002
Dr Maha Othman University of Southampton 2003
Dr Lisa Douet University of Southampton 2008
Dr John Valletta University of Southampton 2011

MD supervision

Dr David Neal University of Southampton 2004
Dr Ruth Poole University of Southampton 2006
Dr Rustom Guzder University of Southampton 2006
Dr Helen Holt University of Southampton 2007
Dr Dinesh Bagmane University of Southampton 2009
Dr Magdalena Turzyniecka University of Southampton 2012
Dr Omar Rana University of Southampton 2012
Dr Natalie Borman University of Southampton 2014

PhD students currently supervised

Dr Loke Bhatia
Keith McCormick
Hugh Thomas
Eleonora Scorletti
Albandri Alshathry
Amal Almehadi

MPhil examiner

University of Newcastle, 2004

MD examiner

University of Newcastle, 2006
University of Southampton 2009
University of Southampton 2013

PhD examiner

University of Belfast, 2004
University of Cambridge, 2005.
University of Southampton, 2008
University of London Imperial, 2009
Peninsula Medical School, University of Plymouth, 2010.
University of Glasgow 2011
University of Cambridge 2014
University of Southampton 2014
Peninsula College of Medicine and Dentistry, University of Exeter and Plymouth, 2015

National and international responsibilities

Committee member of the British Hyperlipidaemia Association (1997-2000).
Committee member Research Grants Diabetes UK 2005-2008
Committee member Lipids section Royal Society of Medicine 2006-
Junior Hon Secretary Lipids, Metabolism & Vascular Risk section
at the Royal Society of Medicine 2008-
Research Grants Committee member. Diabetes UK 2009-2013
Scientific Advisory Committee (SAC) member for the Laboratory of
Developmental Biology (LDB) at Xi’an Jiaotong Liverpool University. June 2010-2014
President RSM Lipids, Metabolism and Vascular Risk section 2013-2016 –
NICE NAFLD Guideline (ng49) Development Group member and Expert Diabetologist Advisor 2014-2016
Faculty member F1000 Prime 2014-

Articles

Sung, K. C., Byrne, C. D., Ryu, S., Lee, J. Y., Lee, S. H., Kim, J. Y., ... Guallar, E. (2017). Baseline and change in uric acid concentration over time are associated with incident hypertension in large Korean cohort. American Journal of Hypertension, 30(1), 42-50. DOI: 10.1093/ajh/hpw091

Hodson, L., Bhatia, L., Scorletti, E., Smith, D. E., Jackson, N. C., Shojaee-Moradie, F., ... Byrne, C. D. (2017). Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. European Journal of Clinical Nutrition, 71(8), 973-978. DOI: 10.1038/ejcn.2017.9

Nobili, V., Alisi, A., Mosca, A., Della Corte, C., Veraldi, S., De Vito, R., ... Byrne, C. (2017). Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver International. DOI: 10.1111/liv.13531

Peters , H. P. F., Schrauwen , P., Verhoef , P., Byrne, C., Mela, D. J., Pfeiffer , A. F. H., ... Schrauwen-Hinderling , V. (2017). Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. Journal of Nutritional Science, 6(e15), 1-13. DOI: 10.1017/jns.2017.13

Lown, M., Fuller, R., Lightowler, H., Fraser, A., Gallagher, A., Stuart, B., ... Lewith, G. (2017). Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study. PLoS ONE, 12(2). DOI: 10.1371/journal.pone.0172239

Nel, K., Nam, M. C. Y., Anstey , C., Boos, C. J., Carlton, E., Senior, R., ... Greaves, K. (2017). Myocardial blood flow reserve is impaired in patients with aortic valve calcification and unobstructed epicardial coronary arteries. International Journal of Cardiology. DOI: 0.1016/j.ijcard.2017.06.023

Valbusa, F., Bonapace, S., Agnoletti, D., Scala, L., Grillo, C., Arduini, P., ... Targher, G. (2017). Non-alcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLOS One, 12(3), e0173398. DOI: 10.1371/journal.pone.0173398

Targher, G., & Byrne, C. (2017). Non-alcoholic fatty liver disease: an emerging driving force in CKD. Nature Reviews Nephrology, 13(5), 297-310. DOI: 10.1038/nrneph.2017.16

Little, P., Stuart, B., Hobbs, F. D. R., Kelly, J., Smith, E., Bradbury, K., ... Yardley, L. (2017). Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction). Health Technology Assessment, 21(4). DOI: 10.3310/hta21040

Mosca, A., Nobili, V., De Vito, R., Crudele, A., Scorletti, E., Villani, A., ... Byrne, C. D. (2017). Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. Journal of Hepatology, 66(5), 1031-1036. DOI: 10.1016/j.jhep.2016.12.025

Rhee, E-J., Byrne, C. D., & Sung, K-C. (2017). The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease. Current Opinion in Endocrinology Diabetes and Obesity, 24(2), 148-153. DOI: 10.1097/MED.0000000000000315

Wainwright, P., Scorletti, E., & Byrne, C. (2017). Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. Current Diabetes Reports, 17(4). DOI: 10.1007/s11892-017-0851-x

Sung, K-C., Ryu, S., Lee, J-Y., Lee, S., Cheong, E., Kim, J-Y., ... Byrne, C. D. (2016). All cause mortality and body mass index in a young Asian occupational cohort without baseline metabolic syndrome components. International Journal of Cardiology, 224, 271-278. DOI: 10.1016/j.ijcard.2016.09.056

Bruce, K., Szczepankiewicz, D., Sihota, K. K., Ravindraanandan, M., Thomas, H., Lillycrop, K. A., ... Cagampang, F. R. (2016). Altered cellular redox status, sirtuin abundance and 1 clock gene expression in a mouse model of developmentally primed NASH. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1-29. DOI: 10.1016/j.bbalip.2016.03.026

Bruce, K. D., Szczepankiewicz, D., Sihota, K. K., Ravindraanandan, M., Thomas, H., Lillycrop, K. A., ... Cagampang, F. R. (2016). Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1861(7), 584-593.

Little, P., Stuart, B., Hobbs, R. F. D., Kelly, J., Smith, E. R., Bradbury, K. J., ... Yardley, L. (2016). An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial. The Lancet Diabetes and Endocrinology, 4(10), 821-828.

Wainwright, P., & Byrne, C. D. (2016). Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. International Journal of Molecular Sciences, 17(3), 1-17. DOI: 10.3390/ijms17030367

Della Corte, C., Carpino, G., De Vito, R., Stefanis, C., Alisi, A., Cianfarani, S., ... Nobili, V. (2016). Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS ONE, 11(12), e0168216.

Byrne, C., & Targher, G. (2016). EASL-EASD-EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease: is universal screening appropriate? Diabetologia, 59(6), 1141-1144.

Wild, S. H., & Byrne, C. D. (2016). Editorial: Body mass index and mortality: understanding the patterns and paradoxes. British Medical Journal, i2433-i2433. DOI: 10.1136/bmj.i2433

Sung, K-C., Ryu, S., Lee, J-Y., Kim, J-Y., Wild, S. H., & Byrne, C. D. (2016). Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. Journal of Hepatology, 65(4), 791-797. DOI: 10.1016/j.jhep.2016.05.026

Scorletti, E., & Byrne, C. (2016). Extrahepatic diseases and NAFLD: The triangular relationship between NAFLD, type 2-diabetes and dysbiosis. Digestive Diseases, 1-23. DOI: 10.1159/000447276

Sung, K. C., Ryu, S., Lee, J. Y., Lee, S. H., Cheong, E. S., Wild, S. H., & Byrne, C. D. (2016). Fatty liver, insulin resistance and obesity: relationships with increase in coronary artery calcium over time. Clinical Cardiology, 39(6), 321-328.

Lonardo, A., Byrne, C., Caldwell, S. H., Cortez-Pinto, H., & Targher, G. (2016). Global epidemiology of non-alcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, 64(4), 1388-1389. DOI: 10.1002/hep.28584

Wainwright, P., Oluwatowoju, I., Ryan, A., Abu, E., & Byrne, C. D. (2016). Glycaemic control and lipid concentrations in a cohort of people with diabetes over 7 years of follow up: a regional audit of diabetes care in the UK. Diabetic Medicine, 33(3), 386-390.

Clough, G., Mccormick, K., Scorletti, E., Bhatia, L., Calder, P., Griffin, M., & Byrne, C. (2016). Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial. Diabetologia, 59(7), 1422-1429. DOI: 10.1007/s00125-016-3966-8

Bhatia, L., Scorletti, E., Curzen, N., Clough, G., Calder, P., & Byrne, C. (2016). Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis, 246, 13-20. DOI: 10.1016/j.atherosclerosis.2015.12.028

Nam, M. C. Y., Byrne, C. D., Kaski, J. C., & Greaves, K. (2016). Insulin in acute coronary syndrome: a narrative review with contemporary perspectives. Cardiovascular Drugs and Therapy, 30(5), 493-504.

Thompson, D., Francis-Emmanuel, P., Barnett, A., Royal - Thomas, T., Osmond, C., Hanson, M., ... Boyne, M. (2016). Insulin sensitivity and insulin clearance in adult survivors of malnutrition. Journal of Clinical Endocrinology and Metabolism, 1-14.

Quah, J., Carlton, E., Rana, O., Byrne, C. D., Senior, R., Anstey, C., & Greaves, K. (2016). Insulin-induced hypoglycaemia and the detection of myocardial injury using an ultrasensitive troponin assay. International Journal of Cardiology, 215, 446-448. DOI: 10.1016/j.ijcard.2016.03.238

Moore, C. E. J., Pickford, J., Cagampang, F. R., Stead, R. S., Tian, S., Zhao, X., ... Proud, C. (2016). MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways. Scientific Reports, 6(23476). DOI: 10.1038/srep23476

Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016). Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. Journal of Hepatology, 65(3), 589-600. DOI: 10.1016/j.jhep.2016.05.013

Valbusa, F., Bonapace, S., Grillo, C., Scala, L., Chiampan, A., Rossi, A., ... Targher, G. (2016). Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine, 95(7), e2760. DOI: 10.1097/MD.0000000000002760

Targher, G., & Byrne, C. (2016). Obesity: metabolically healthy obesity and NAFLD. Nature Reviews Gastroenterology & Hepatology, 13(8), 442-444. DOI: 10.1038/nrgastro.2016.104

Nobili, V., Alisi, A., Musso, G., Scorletti, E., Calder, P. C., & Byrne, C. D. (2016). Omega-3 Fatty Acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Critical Reviews in Clinical Laboratory Sciences, 53(2), 106-120.

Targher, G., Marchesini, G., & Byrne, C. (2016). Risk of Type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon. Diabetes & Metabolism, 42(3), 142-156.

Wild, S. H., Morling, J. R., McAllister, D. A., Kerssens, J., Fischbacher, C., Parkes, J., ... Byrne, C. (2016). Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. Journal of Hepatology, 64(6), 1358-1364. DOI: 10.1016/j.jhep.2016.01.014

Sung, K. C., Ryu, S., Lee, J. Y., Lee, S. H., Cheong, E. S., Hyun, Y. Y., ... Byrne, C. (2016). Urine albumin/creatinine ratio below 30mg/g is a predictor of incident hypertension and cardiovascular mortality. Journal of the American Heart Association, 5(9), 1-12. DOI: 10.1161/JAHA.116.003245

Ewings, S. M., Sahu, S. K., Valletta, J. J., Byrne, C. D., & Chipperfield, A. J. (2015). A Bayesian network for modelling blood glucose concentration and exercise in type 1 diabetes. Statistical Methods in Medical Research, 24(3), 342-372. DOI: 10.1177/0962280214520732

Targher, G., & Byrne, C. D. (2015). A perspective on metabolic syndrome and nonalcoholic fatty liver disease. Metabolic Syndrome and Related Disorders, 13(6), 235-238. DOI: 10.1089/met.2015.1502

Sung, K. C., Ryu, S., Cheong, E. S., Kim, B. S., Kim, B. J., Kim, Y. B., ... Byrne, C. D. (2015). All-cause and cardiovascular mortality among Koreans: effects of obesity and metabolic health. American Journal of Preventive Medicine, 49(1), 62-71. DOI: 10.1016/j.amepre.2015.02.010

Sung, K. C., Ryu, S., Wild, S. H., & Byrne, C. D. (2015). An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart, 101(7), 553-558. DOI: 10.1136/heartjnl-2014-306784

Kim, N. H., So, M. S., Kang, J. G., Cho, D. S., Byrne, C. D., Lee, S. J., & Sung, K. C. (2015). Application of new guidelines for the primary prevention of atherosclerotic cardiovascular disease in a Korean population. Journal of Atherosclerosis and Thrombosis, 22(3), 293-303. DOI: 10.5551/jat.26682

Targher, G., & Byrne, C. D. (2015). Circulating markers of liver function and cardiovascular disease risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2290-2296.

Sung, K. C., Sung, E., Byrne, C. D., Kim, Y. B., Ahn, C. W., & Chung, H. (2015). Composition of dietary macronutrient intake is not associated with prevalence of coronary artery calcification in healthy Korean adults. Annals of Nutrition and Metabolism, 66(1), 36-43. DOI: 10.1159/000369563

Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., ... Targher, G. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Digestive and Liver Disease, 47(12), 997-1006. DOI: 10.1016/j.dld.2015.08.004

Targher, G., & Byrne, C. D. (2015). Gallstone disease and increased risk of ischemic heart disease: causal association or epiphenomenon? Arteriosclerosis, Thrombosis, and Vascular Biology, 35(10), 2073-2075.

Sung, K. C., Ryu, S., Kim, B. S., Cheong, E. S., Park, D. I., Kim, B. I., ... Byrne, C. D. (2015). Gamma glutamyl transferase is associated with mortality outcomes independently of fatty liver. Clinical Chemistry, 61(9), 1173-1181. DOI: 10.1373/clinchem.2015.240424

Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Valbusa, F., ... Targher, G. (2015). Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism Clinical and Experimental. DOI: 10.1016/j.metabol.2015.04.003

McCormick, K., Scorletti, E., Bhatia, L., Calder, P. C., Griffin, M. J., Clough, G. F., & Byrne, C. D. (2015). Impact of high dose omega-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia, 58(8), 1916-1925. DOI: 10.1007/s00125-015-3628-2

Ryan, A., & Byrne, C. D. (2015). Importance of early recognition of heterozygous familial hypercholesterolaemia. Current Opinion in Lipidology, 26(4), 298-303.

Sung, K. C., Rhee, E. J., Ryu, S., Kim, B. J., Kim, B. S., Lee, W. Y., ... Park, S. W. (2015). Increased cardiovascular mortality in subjects with metabolic syndrome is largely attributable to diabetes and hypertension in 159,971 Korean adults. Journal of Clinical Endocrinology and Metabolism, 100(7), 2606-2612.

Lown, M., Fuller, R., Lightowler, H., Fraser, A., Gallagher, A., Stuart, B., ... Lewith, G. (2015). Mulberry extract to modULate Blood glucosE Responses in noRmoglYcaemic adults (MULBERRY): study protocol for a randomized controlled trial. Trials, 486. DOI: 10.1186/s13063-015-0997-2

Byrne, C. D., & Targher, G. (2015). NAFLD: A multisystem disease. Journal of Hepatology, 62(1), S47-S64. DOI: 10.1016/j.jhep.2014.12.012

Byrne, C. D., & Targher, G. (2015). Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology, 7-10. DOI: 10.1053/j.gastro.2015.11.016

Scorletti, E., West, A. L., Bhatia, L., Hoile, S. P., McCormick, K., Burdge, G. C., ... Byrne, C. D. (2015). Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. Journal of Hepatology, 63(6), 1476-1483. DOI: 10.1016/j.jhep.2015.07.036

Rowsell, A., Muller, I., Murray, E., Little, P., Byrne, C., Ganahl, K., ... Yardley, L. (2015). Views of people with high and low levels of health literacy about a digital intervention to promote physical activity for diabetes: a qualitative study in five countries. Journal of Medical Internet Research, 17(10), 1-12. DOI: 10.2196/jmir.4999

Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Pichiri, I., ... Byrne, C. D. (2014). Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 24(6), 663-669. DOI: 10.1016/j.numecd.2014.01.005

Targher, G., Chonchol, M., & Byrne, C. D. (2014). CKD and nonalcoholic fatty liver disease. American Journal of Kidney Diseases, 64(4), 638-652. DOI: 10.1053/j.ajkd.2014.05.019

Sung, K. C., Ryu, S., Chang, Y., Byrne, C. D., & Kim, S. (2014). C-reactive protein and risk of cardiovascular and all-cause mortality in 268,803 East Asians. European Heart Journal, 35(27), 1809-1816. DOI: 10.1093/eurheartj/ehu059

Valletta, J. J., Chipperfield, A. J., Clough, G. F., & Byrne, C. D. (2014). Daily energy expenditure, cardiorespiratory fitness and glycaemic control in people with type 1 diabetes. PLoS ONE, 9(5). DOI: 10.1371/journal.pone.0097534

Scorletti, E., Bhatia, L., McCormick, K., Clough, G. F., Nash, K., Calder, P. C., & Byrne, C. D. (2014). Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemporary Clinical Trials, 37(2), 301-311. DOI: 10.1016/j.cct.2014.02.002

Sung, K. C., Wild, S. H., & Byrne, C. D. (2014). Development of new fatty liver, or resolution of existing fatty liver, over five years of follow up, and risk of incident hypertension. Journal of Hepatology, 60(5), 1040-1045. DOI: 10.1016/j.jhep.2014.01.009

Byrne, C. D., & Targher, G. (2014). Ectopic fat, insulin resistance, and nonalcoholic Fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(6), 1155-1161. DOI: 10.1161/?ATVBAHA.114.303034

Scorletti, E., Bhatia, L., McCormick, K., Clough, G. F., Nash, K., Hodson, L., ... Byrne, C. D. (2014). Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the WELCOME study. Hepatology, 60, 1211-1221. DOI: 10.1002/hep.27289

Lamb, M. J. E., Byrne, C. D., Wilson, J. F., & Wild, S. H. (2014). Evaluation of bioelectrical impedance analysis for identifying overweight individuals at increased cardiometabolic risk: a cross-sectional study. PLoS ONE, 9(9), e106134. DOI: 10.1371/journal.pone.0106134

Francis-Emmanuel, P. M., Thompson, D. S., Barnett, A. T., Osmond, C., Byrne, C. D., Hanson, M. A., ... Boyne, M. S. (2014). Glucose metabolism in adult survivors of severe acute malnutrition. Journal of Clinical Endocrinology and Metabolism, 99(6), 2233-2240. DOI: 10.1210/jc.2013-3511

Sung, J. W., Lee, S. H., Byrne, C. D., Chung, P. W., Won, Y. S., & Sung, K. C. (2014). High-sensitivity C-reactive protein is associated with the presence of coronary artery calcium in subjects with normal blood pressure but not in subjects with hypertension. Archives of Medical Research, 45(2), 170-176. DOI: 10.1016/j.arcmed.2014.01.003

Rana, O. A., Byrne, C. D., & Greaves, K. (2014). Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart, 100(1), 21-27. DOI: 10.1136/heartjnl-2013-303871

Targher, G., & Byrne, C. D. (2014). Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link? Endocrine, 47(1), 3-4. DOI: 10.1007/s12020-014-0220-3

Sung, K. C., Cha, S. C., Sung, J. W., So, M. S., & Byrne, C. D. (2014). Metabolically healthy obese subjects are at risk of fatty liver but not pre-clinical atherosclerosis. Nutrition, Metabolism & Cardiovascular Diseases, 24(3), 256-262. DOI: 10.1016/j.numecd.2013.07.005

Targher, G., Mantovani, A., Pichiri, I., Mingolla, L., Cavalieri, V., Mantovani, W., ... Bonora, E. (2014). Nonalcoholic Fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care, 37(6), 1729-1736. DOI: 10.2337/dc13-2704

Yardley, L., Ware, L. J., Smith, E. R., Williams, S., Bradbury, K. J., Arden-Close, E., ... Little, P. (2014). Randomised controlled feasibility trial of a web-based weight management intervention with nurse support for obese patients in primary care. International Journal of Behavioral Nutrition and Physical Activity, 11(1), 67. DOI: 10.1186/1479-5868-11-67

Ballestri, S., Lonardo, A., Bonapace, S., Byrne, C. D., Loria, P., & Targher, G. (2014). Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 20(7), 1724-1745. DOI: 10.3748/wjg.v20.i7.1724

Pears, R., Griffin, M., Watson, M., Wheeler, R., Hilder, D., Meeson, B., ... Byrne, C. D. (2014). The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. Open Heart, 1(1). DOI: 10.1136/openhrt-2013-000015

Summers, R. H., Elsey, H., Moore, M., Byrne, C., Byrne, J., Welbourn, R., & Roderick, P. (2014). Weight loss surgery for non-morbidly obese populations with type 2 diabetes: is this an acceptable option for patients? Primary Health Care Research & Development, 15(3), 277-286. DOI: 10.1017/S146342361300025X

Sung, K-S., Wild, S. H., & Byrne, C. D. (2013). Controlling for Apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. Atherosclerosis, 231(2), 181-186. DOI: 10.1016/j.atherosclerosis.2013.09.009

Targher, G., & Byrne, C. D. (2013). Diagnosis and management of non-alcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Seminars in Thrombosis and Hemostasis, 39(2), 214-228.

Byrne, C. D. (2013). Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proceedings of the Nutrition Society, 1-8. DOI: 10.1017/S0029665113001249

Saunders, C., Byrne, C. D., Guthrie, B., Lindsay, R. S., McKnight, J. A., Philip, S., ... Wild, S. H. (2013). External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabetic Medicine, 30(3), 300-308. DOI: 10.1111/dme.12047

Kwan, J., Horsfield, G., Bryant, T., Gawne-Caine, M., Durward, G., Byrne, C. D., & Englyst, N. A. (2013). IL-6 is a predictive biomarker for stroke associated infection and future mortality in the elderly after an ischemic stroke. Experimental Gerontology, 48(9), 960-965. DOI: 10.1016/j.exger.2013.07.003

Rajendran, R., Abu, E., Fadl, A., & Byrne, C. D. (2013). Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood total body irradiation. Diabetic Medicine, 30(8), e239-e242. DOI: 10.1111/dme.12234

Sung, K-C., Wild, S. H., & Byrne, C. D. (2013). Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutrition, Metabolism and Cardiovascular Diseases, 23(12), 1239-1246. DOI: 10.1016/j.numecd.2013.02.009

Targher, G., Scorletti, E., Mantovani, A., & Byrne, C. D. (2013). Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D3 levels. Metabolic Syndrome and Related Disorders, 11(4), 217-228. DOI: 10.1089/met.2013.0044

Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., ... Byrne, C. D. (2013). Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE, 8(2), e57183. DOI: 10.1371/journal.pone.0057183

Targher, G., & Byrne, C. D. (2013). Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism, 98(2), 483-495. DOI: 10.1210/jc.2012-3093

Scorletti, E., & Byrne, C. D. (2013). Omega-3 fatty acids, hepatic lipid metabolism and non-alcoholic fatty liver disease. Annual Review of Nutrition, 33, 231-248.

Sung, K-C., Shin, J., Lim, Y-H., Wild, S. H., & Byrne, C. D. (2013). Relation of conjugated bilirubin concentrations to the presence of coronary artery calcium. The American Journal of Cardiology, 112(12), 1873-1879. DOI: 10.1016/j.amjcard.2013.08.018

Valbusa, F., Bertolini, L., Bonapace, S., Zenari, L., Zoppini, G., Arcaro, G., ... Targher, G. (2013). Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology, 112(4), 499-504. DOI: 10.1016/j.amjcard.2013.04.012

Sung, K. C., Wild, S. H., & Byrne, C. D. (2013). Resolution of fatty liver and risk of incident diabetes. Journal of Clinical Endocrinology and Metabolism, 98(9), 3637-3643. DOI: 10.1210/jc.2013-1519

Wild, S. H., & Byrne, C. D. (2013). Towards a personalised diagnosis of type 2 diabetes. The Lancet Diabetes and Endocrinology, 1(1), 6-7.

Sung, K-C., Jeong, W-S., Wild, S. H., & Byrne, C. D. (2012). Combined influence of insulin resistance, overweight/obesity and fatty liver as risk factors for type 2 diabetes. Diabetes Care, 35(4), 717-722. DOI: 10.2337/dc11-1853

Byrne, C. D. (2012). Dorothy Hodgkin lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetic Medicine, 29(9), 1098-1107. DOI: 10.1111/j.1464-5491.2012.03732.x

Cho, D-S., Woo, S., Kim, S., Byrne, C. D., Sung, K-C., & Kong, J-H. (2012). Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovascular Diabetology, 11(1), 55. DOI: 10.1186/1475-2840-11-55

Sung, K. C., Wild, S. H., Kwag, H. J., & Byrne, C. D. (2012). Fatty liver, insulin resistance and features of metabolic syndrome: relationships with coronary artery calcium in 10153 people. Diabetes Care, 35(11), 2359-2364.

Sung, K. C., Kang, S-M., Cho, E-J., Park, J. B., Wild, S. H., & Byrne, C. D. (2012). Ferritin is independently associated with the presence of coronary artery calcium in 12033 men. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(10), 2525-2530.

Torrens, C., Ethirajan, P., Bruce, K. D., Cagampang, F. R., Siow, R. C., Hanson, M. A., ... Clough, G. F. (2012). Interaction between maternal and offspring diet to impair vascular function and oxidative balance in high fat fed male mice. PLoS ONE, 7(12), e0050671. DOI: 10.1371/journal.pone.0050671

Valletta, J. J., Chipperfield, A. J., Clough, G. F., & Byrne, C. D. (2012). Metabolic regulation during constant moderate physical exertion in extreme conditions in Type 1 diabetes. Diabetic Medicine, 29(6), 822-826.

Bhatia, L. S., Curzen, N., & Byrne, C. D. (2012). Nonalcoholic fatty liver disease and vascular risk. Current Opinion in Cardiology, 27(4), 420-428. DOI: 10.1097/HCO.0b013e328354829c

Bhatia, L. S., Curzen, N., & Byrne, C. D. (2012). Non-alcoholic fatty liver disease and vascular risk. Current Opinion in Cardiology, 27(4), 420-428.

Bhatia, L. S., Curzen, N., Calder, P. C., & Byrne, C. D. (2012). Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor. European Heart Journal, 33(10), 1190-200.

Sung, K. C., Kim, B. S., Cho, Y. K., Park, D. I., Woo, S., Kim, S., ... Byrne, C. D. (2012). Predicting incident fatty liver using simple cardiometabolic risk factors at baseline. BMC Gastroenterology, 12(1), p.84. DOI: 10.1186/1471-230X-12-84

Wild, S. H., & Byrne, C. D. (2012). Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus. Evidence-Based Medicine, 17(6), 192-193.

Bruce, K. D., Sihota, K., Byrne, C. D., & Cagampang, F. (2012). The housekeeping gene YWHAZ remains stable in a model of developmentally primed non alcoholic fatty liver disease. Liver International, 32(8), 1315-1321.

Hyde, M. J., Clarke, L., Griffin, J. L., Herrera, E., Byrne, C. D., & Kemp, P. R. (2011). A single enteral feed prior to the commencement of parenteral nutrition ameliorates the incidence of steatosis in parenterally fed neonatal piglets. Metabolomics, 7, 118-125. DOI: 10.1007/s11306-010-0237-4

Rana, O., Byrne, C. D., Kerr, D., Coppini, D., Zouwail, S., Senior, R., ... Greaves, K. (2011). Acute Hypoglycemia Decreases Myocardial Blood Flow Reserve in Patients With Type 1 Diabetes Mellitus and in Healthy Humans. Circulation, 124(14), 1548-1556. DOI: 10.1161/CIRCULATIONAHA.110.992297

Clough, G. F., L'Esperance, V., Walter, L., Chipperfield, A. J., Gamble, J., Krentz, A. J., & Byrne, C. D. (2011). Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatment. International Journal of Microcirculation, 18(1), 74-84. DOI: 10.1111/j.1549-8719.2010.00070.x

Bruce, K. D., Stokes, A., Patel, N. R., Hyde, K., Sadek, K. H., Hanson, M. A., ... Cagampang, F. R. (2011). Identification of robust cardiac reference genes in a mouse model of cardiometabolic disease. Journal of Clinical and Experimental Cardiology, 10(2). DOI: 10.4172/2155-9880.1000161

Byrne, C. D., & Wild, S. H. (2011). Increased risk of glucose intolerance and type 2 diabetes with statins. British Medical Journal, 343.

Scorletti, E., Calder, P. C., & Byrne, C. D. (2011). Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine, 40(3), 332-343. DOI: 10.1007/s12020-011-9530-x

Ahmed, M. H., & Byrne, C. D. (2010). Bariatric surgery and chronic kidney disease: an intriguing relationship. Nephrology, Dialysis, Transplantation, 25(12), 4117-4118. DOI: 10.1093/ndt/gfq347

Ahmed, M. H., & Byrne, C. D. (2010). Bariatric surgery and renal function: a precarious balance between benefit and harm. Nephrology, Dialysis, Transplantation, 25(10), 3142-3147. DOI: 10.1093/ndt/gfq347

Byrne, C. D. (2010). Commentary. Hypoxia and non alcoholic fatty liver disease. Clinical Science, 118, 397-400. DOI: 10.1042/CS20090565

Clough, G. F., Avery, M. R., Voegeli, D., Byrne, C. D., & Simpson, D. M. (2010). Cutaneous vascular response to local warming: a response to letter from Cracowski and Roustit. Microcirculation, 17(2), 81-82. DOI: 10.1111/j.1549-8719.2010.00019.x

Hyde, M. J., Griffin, J. L., Herrera, E., Byrne, C. D., Clarke, L., & Kemp, P. R. (2010). Delivery by Caesarean section, rather than vaginal delivery, promotes hepatic steatosis in piglets. Clinical Science, 118(1), 47-59. DOI: 10.1042/CS20090169

Turzyniecka, M., Wild, S. H., Krentz, A. J., Chipperfield, A. J., Clough, G. F., & Byrne, C. D. (2010). Diastolic function is strongly and independently associated with cardio-respiratory fitness in central obesity. Journal of Applied Physiology, 108(6), 1568-1574. DOI: 10.1152/japplphysiol.00023.2010

Byrne, C. D., & Wild, S. H. (2010). Editorial. Body fat and increased risk of cirrhosis: better diagnosis and treatment of non-alcoholic fatty liver disease are needed. BMJ, 340, c774. DOI: 10.1136/bmj.c774

Ahmed, M. H., & Byrne, C. D. (2010). Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discovery Today, 15(15-16), 590-595. DOI: 10.1016/j.drudis.2010.06.007

Byrne, C. D. (2010). Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins, Leukotrienes and Essential Fatty Acids, 82(4-6), 265-271. DOI: 10.1016/j.plefa.2010.02.012

Rana, O., Byrne, C. D., & Greaves, K. (2010). Intensive insulin therapy in the intensive care unit, hypoglycemia and cardiovascular mortality. Hospital Practice, 38(2), 59-66. DOI: 10.3810/hp.2010.04.295

Ahmed, M. H., Abu, E. O., & Byrne, C. D. (2010). Non alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Primary Care Diabetes, 4(3), 129-137. DOI: 10.1016/j.pcd.2010.02.004

Ahmed, M. H., & Byrne, C. D. (2010). Obstructive sleep apnea syndrome and fatty liver: association or causal link? World Journal of Gastroenterology, 16(34), 4243-4252.

Ahmed, M. H., & Byrne, C. D. (2010). Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes, Obesity and Metabolism, 12(11), 958-966. DOI: 10.1111/j.1463-1326.2010.01261.x

Bhatia, L., & Byrne, C. D. (2010). There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evidence-Based Medicine, 15(3), 84-85. DOI: 10.1136/ebm1075

Avery, M. R., Voegeli, D., Simpson, D., Clough, G. F., & Byrne, C. D. (2009). Age and cigarette smoking are independently associated with the cutaneous vascular response to local warming. Microcirculation, 16(8), 725-734. DOI: 10.3109/10739680903199194

Clough, G. F., Chipperfield, A., Byrne, C., de Mul, F., & Gush, R. (2009). Evaluation of a new high power, wide separation laser Doppler probe: potential measurement of deeper tissue blood flow. Microvascular Research, 78(2), 155-161. DOI: 10.1016/j.mvr.2009.05.003

Oluwatowoju, I., Abu, E., Wild, S. H., & Byrne, C. D. (2009). Improvements in glycaemic control and cholesterol concentrations associated with the quality and outcomes framework: a regional 2 year audit of diabetes care in the UK. Diabetic Medicine, 27, 354-360. DOI: 10.1111/j.1464-5491.2009.02951.x

Zhang, J., Zhang, F., Didelot, X., Bruce, K. D., Cagampang, F. R., Vatish, M., ... Byrne, C. D. (2009). Maternal high fat diet during pregnancy and lactation alters hepatic expression of insulin like growth factor-2 and key microRNAs in the adult offspring. BMC Genomics, 10(478), 1-12. DOI: 10.1186/1471-2164-10-478

Bruce, K. D., Cagampang, F. R., Argenton, M., Zhang, J., Ethirajan, P. L., Burdge, G. C., ... Byrne, C. D. (2009). Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology, 50(6), 1796-1808. DOI: 10.1002/hep.23205

Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009). Metabolic disturbances in non-alcoholic fatty liver disease. Clinical Science, 116(7), 539-564. DOI: 10.1042/CS20080253

Wild, S. H., Byrne, C. D., Tzoulaki, I., Lee, A. J., Rumley, A., Lowe, G. D. O., & Fowkes, F. G. R. (2009). Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study. Atherosclerosis, 203(2), 604-609. DOI: 10.1016/j.atherosclerosis.2008.07.028

Clough, G. F., Turzyniecka, M., Walter, L., Krentz, A. J., Wild, S. H., Chipperfield, A. J., ... Byrne, C. D. (2009). Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but Is not reversed by high-dose statin treatment. Diabetes, 58(5), 1185-1191. DOI: 10.2337/db08-1688

Turzyniecka, M., Wild, S. H., Krentz, A. J., Chipperfield, A. J., Gamble, J., Clough, G. F., & Byrne, C. D. (2009). Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesity. Diabetic Medicine, 26(11), 1112-1119. DOI: 10.1111/j.1464-5491.2009.02822.x

Richardson, M. C., Ingamells, S., Simonis, C. D., Cameron, I. T., Sreekumar, R., Vijendren, A., ... Coakley, S. (2009). Stimulation of lactate production in human granulosa cells by metformin and potential involvement of adenosine 5' monophosphate-activated protein kinase. Journal of Clinical Endocrinology and Metabolism, 94(2), 670-677. DOI: 10.1210/jc.2008-2025

Bruce, K. D., & Byrne, C. D. (2009). The metabolic syndrome: common origins of a multifactorial disorder. Postgraduate Medical Journal, 85(1009), 614-621. DOI: 10.1136/pgmj.2008.078014

Krentz, A. J., Clough, G., & Byrne, C. D. (2009). Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? Journal of Vascular Research, 46(6), 515-526. DOI: 10.1159/000226220

Ethirajan, P., Torrens, C., Bruce, K., Cagampang, F., Hanson, M. A., Byrne, C. D., & Clough, G. F. (2008). A potential mechanism for impaired vasorelaxation in a dietary model of metabolic syndrome. Journal of Vascular Research, 45(Supplement 2), 167. DOI: 10.1159/000144991

Englyst, N. A., Horsfield, G., Kwan, J., & Byrne, C. D. (2008). Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. Journal of Cerebral Blood Flow & Metabolism, 28(6), 1196-1203. DOI: 10.1038/jcbfm.2008.9

Olufadi, R., & Byrne, C. D. (2008). Clinical and laboratory diagnosis of the metabolic syndrome. Journal of Clinical Pathology, 61(6), 697-706. DOI: 10.1136/jcp.2007.048363

Byrne, C. D., & Wild, S. H. (2008). Commentary: Thiazolidinediones increase risk of heart failure in type 2 diabetes. Evidence-Based Medicine, 13(1), 8. DOI: 10.1136/ebm.13.1.8

Ahmed, M. H., & Byrne, C. D. (2008). Current treatment of non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 11(3), 188-195. DOI: 10.1111/j.1463-1326.2008.00926.x

Clough, G. F., L'Esperance, V., Turzyniecka, M., Krentz, A., & Byrne, C. D. (2008). Decreased microvascular funtional vasodilatory reserve and features of the metabolic syndrome. FASEB Journal, 22.

Wild, S., & Byrne, C. D. (2008). Editorial. Time to rethink high-density lipoprotein? Heart, 94(6), 692-694. DOI: 10.1136/hrt.2007.126326

Bruce, K. D., Argenton, M., Cagampang, F., McConnell, J., Poston, L., Hanson, M., & Byrne, C. (2008). Exposure to a high fat, and low carbohydrate diet in utero and during lactation modulates hepatic mitochondrial complex activity. Proceedings of the Physiological Society, 11(C108).

Byrne, C. D., & Wild, S. H. (2008). Review: thiazolidinediones increase risk of heart failure in type 2 diabetes. ACP Journal Club, 148(1), 5-5.

Englyst, N. A., Horsfield, G., & Byrne, C. D. (2007). Aspirin resistance is associated with inflammation, ischemic stroke severity and poorer functional outcome at 6 months. Cerebrovascular Diseases, 23(Supplement 2), pp.103. DOI: 10.1159/000103855

Wild, S. H., Bryden, J. R., Lee, R. J., Bishop, J. L., Finlayson, A. R., Byrne, C. D., & Brewster, D. H. (2007). Cancer, cardiovascular disease and diabetes mortality among women with a history of endometrial cancer. British Journal of Cancer, 96(11), 1747-1749. DOI: 10.1038/sj.bjc.6603761

Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., ... Byrne, C. D. (2007). Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia, 50(5), 1024-1032. DOI: 10.1007/s00125-007-0629-9

Holt, H. B., Wild, S. H., Wareham, N., Ekelund, U., Umpleby, M., Shojaee-Moradie, F., ... Byrne, C. D. (2007). Differential effects of fatness, fitness and physical activity energy expenditure on whole-body, liver and fat insulin sensitivity. Diabetologia, 50(8), 1698-1706. DOI: 10.1007/s00125-007-0705-1

Ahmed, M. H., & Byrne, C. D. (2007). Drug treatment and type 2 diabetes: the impact of liver disease. Practical Diabetes International, 24(6), 318-323. DOI: 10.1002/pdi.1132

Guzder, R. N., Gatling, W., Mullee, M. A., & Byrne, C. D. (2007). Early mortality from the time of diagnosis of Type 2 diabetes: a 5-year prospective cohort study with a local age- and sex-matched comparison cohort. Diabetic Medicine, 24(10), 1164-1167. DOI: 10.1111/j.1464-5491.2007.02223.x

Sayer, A. A., Syddall, H. E., Dennison, E. M., Martin, H. J., Phillips, D. I., Cooper, C., & Byrne, C. D. (2007). Grip strength and the metabolic syndrome: findings from the Hertfordshire cohort study. QJM: An International Journal of Medicine, 100(11), 707-713. DOI: 10.1093/qjmed/hcm095

Byrne, C. D., Wild, S. H., Phillips, D. I., & Holt, H. (2007). Insulin resistance and cortisol metabolism. Reply to Kerstens MN, Dullaart RPF [letter]. Diabetologia, 50(9), 2025-2026. DOI: 10.1007/s00125-007-0741-x

Turzyniecka, M. J., Ung, J. C. C., Krentz, A. J., Clough, G. F., & Byrne, C. D. (2007). Insulin vascular action in skeletal muscle is attenuated with insulin resistance and features of metabolic syndrome. Diabetologia, 50(Supplement 1), S291.

Krentz, A. J., Clough, G., & Byrne, C. D. (2007). Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes, Obesity and Metabolism, 9(6), 781-791.

Englyst, N. A., Grimble, R. F., & Byrne, C. D. (2007). Long-chain n-3 fatty acid supplementation in men increases resistance to activated protein C. Metabolism, 56(4), 547-551. DOI: 10.1016/j.metabol.2006.11.017

Ahmed, M. H., & Byrne, C. D. (2007). Modulation of Sterol Regulatory Element-Binding Proteins (SREBPs) as potential treatments for Non-alcoholic Fatty Liver Disease (NAFLD). Drug Discovery Today, 12(17/18), 740-747. DOI: 10.1016/j.drudis.2007.07.009

Walter, L., Turzyniecka, M., Byrne, C. D., Gamble, J., & Clough, G. F. (2007). Muscle microvascular filtration capacity and blood flow in metabolic syndrome. Microcirculation, 14(6), p.645. DOI: 10.1080/10739680701410785

Ung, J. C. C., Turzyniecka, M., & Clough, G. F. (2007). Relationship between muscle blood flow and insulin sensitivity in metabolica syndrome. Microcirculation, 14(6), p.658. DOI: 10.1080/10739680701410785

Ahmed, M., & Byrne, C. (2007). Treating non-alcoholic fatty liver disease. Practice Nursing, 18(3), 120-126.

Othman, M., Elbatarny, H. S., Byrne, C. D., & O'Shaughnessy, D. F. (2007). Von Willebrand factor short sequence repeat locus 2 (intron 40) consists of three polymorphic subloci. Acta Haematologica, 117(3), 177-180. DOI: 10.1159/000097660

Bruce, K. D., Sellayah, D., Barnet-Lamb, E., Anthony, F. W., Wang, C., Hanson, M. A., ... Byrne, C. D. (2006). A high unsaturated fat, high protein, and low carbohydrate diet during pregnancy and lactation modulates peripheral adipokine receptor gene expression in adult mouse offspring. Early Human Development, 82(8), 494-495. DOI: 10.1016/j.earlhumdev.2006.06.003

Wild, S. H., & Byrne, C. D. (2006). ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ, 333(7576), 1009-1011. DOI: 10.1136/bmj.39024.568738.43

Reynolds, R. M., Fischbacher, C., Bhopal, R., Byrne, C. D., White, M., Unwin, N., & Walker, B. R. (2006). Differences in cortisol concentrations in South Asian and European men living in the United Kingdom. Clinical Endocrinology, 64(5), 530-534. DOI: 10.1111/j.1365-2265.2006.02504.x

Olufadi, R., & Byrne, C. D. (2006). Effects of VLDL and remnant particles on platelets. Pathophysiology of Haemostasis and Thrombosis, 35(3-4), 281-291. DOI: 10.1159/000093221

Sellayah, D., Bruce, K. D., Wang, C., Anthony, F. W., Hanson, M. A., Byrne, C. D., & Cagampang, F. R. (2006). High fat and protein diet during pregnancy and lactation alters hypothalamic adiponectin receptor gene expression in adult mouse offspring. Early Human Development, 82(8), pp.503. DOI: 10.1016/j.earlhumdev.2006.06.003

Guzder, R. N., Gatling, W., Mullee, M. A., & Byrne, C. D. (2006). Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia, 49(1), 49-55. DOI: 10.1007/s00125-005-0063-9

Wild, S. H., Byrne, C. D., Smith, F. B., Lee, A. J., & Fowkes, F. G. (2006). Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the edinburgh artery study. Diabetes Care, 29(3), 637-642. DOI: 10.2337/diacare.29.03.06.dc05-1637

Wild, S. H., & Byrne, C. D. (2006). Metabolic syndrome as a risk indicator. MIMS Cardiovascular, 1(1), 18-21.

Holt, H. B., Wild, S. H., Wood, P. J., Zhang, J., Darekar, A. A., Dewbury, K., ... Byrne, C. D. (2006). Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia, 49(1), 141-148. DOI: 10.1007/s00125-005-0070-x

Englyst, N. A., Crook, M. A., Lumb, P., Stears, A. J., Masding, M. G., Wootton, S. A., ... Byrne, C. D. (2006). Percentage of body fat and plasma glucose predict plasma sialic acid concentration in type 2 diabetes mellitus. Metabolism, 55(9), 1165-1170. DOI: 10.1016/j.metabol.2006.04.014

Poole, R. B., Harrold, C. P., Burridge, J. H., Byrne, C. D., & Holt, R. I. G. (2005). Electrical muscle stimulation acutely mimics exercise in neurologically intact individuals but has limited clinical benefits in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 7(4), 344-351. DOI: 10.1111/j.1463-1326.2004.00400.x

Zhang, J., Holt, H., Wang, C., Hadid, O. H., & Byrne, C. D. (2005). Expression of AdipoR1 in vivo in skeletal muscle is independently associated with measures of truncal obesity in middle-aged Caucasian men. Diabetes Care, 28(8), 2058-2060. DOI: 10.2337/diacare.28.8.2058

Zhang, J., Wang, C., Terroni, P. L., Cagampang, F. R. A., Hanson, M., & Byrne, C. D. (2005). High-unsaturated-fat, high-protein, and low-carbohydrate diet during pregnancy and lactation modulates hepatic lipid metabolism in female adult offspring. American Journal of Physiology- Regulatory, Integrative and Comparative Physiology, 288(1), R112-R118. DOI: 10.1152/ajpregu.00351.2004

Othman, M., Notley, C., Lavender, F. L., White, H., Byrne, C. D., Lillicrap, D., & O'Shaughnessy, D. F. (2005). Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood, 105(11), 4330-4336. DOI: 10.1182/blood-2002-09-2942

Richardson, M. C., Cameron, I. T., Simonis, C. D., Das, M. C., Hodge, T. E., Zhang, J., & Byrne, C. D. (2005). Insulin and human chorionic gonadotropin cause a shift in the balance of sterol regulatory element-binding protein (SREBP) isoforms toward the SREBP-1c isoform in cultures of human granulosa cells. Journal of Clinical Endocrinology and Metabolism, 90(6), 3738-3746. DOI: 10.1210/jc.2004-2057

Patel, M. B. R., Arden, N. K., Masterson, L. M., Phillips, D. I. W., Swaminathan, R., Syddall, H. E., ... Holt, R. I. G. (2005). Investigating the role of the growth hormone-insulin-like growth factor (GH-IGF) axis as a determinant of male bone mineral density (BMD). Bone, 37(6), 833-841. DOI: 10.1016/j.bone.2005.06.016

Zhang, J., Holt, R. I. G., Wild, S. H., Poole, R. B., Holt, H., & Byrne, C. D. (2005). Letters: observations. Plasma adiponectin concentrations are independently predicted by fat insulin sensitivity in women and by muscle insulin sensitivity in men. Diabetes Care, 28(3), 755-756. DOI: 10.2337/diacare.28.3.755

Zhang, J., Lewis, R. M., Wang, C., Hales, N., & Byrne, C. D. (2005). Maternal dietary iron restriction modulates hepatic lipid metabolism in the fetuses. American Journal of Physiology- Regulatory, Integrative and Comparative Physiology, 288(1), R104-R111. DOI: 10.1152/ajpregu.00343.2004

Guzder, R. N., Gatling, W., Mullee, M. A., Mehta, R. L., & Byrne, C. D. (2005). Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabetic Medicine, 22(5), 554-562. DOI: 10.1111/j.1464-5491.2005.01494.x

Byrne, C. D. (2005). Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. ACP Journal Club, 142(1), 18-18.

Byrne, C. D., & Wild, S. H. (2005). Review: orlistat and sibutramine are modestly effective for weight loss at 1 year. ACP Journal Club, 142(1), 19-19.

Poole, R., & Byrne, C. D. (2005). The metabolic syndrome and type 2 diabetes. Minerva Endocrinologica, 30(3), 139-159.

Wild, S. H., & Byrne, C. D. (2005). Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes. British Journal of Diabetes and Vascular Disease, 5(6), 315-319.

Feest, T. G., Rajamahesh, J., Byrne, C., Ahmad, A., Ansell, D., Burden, R., & Roderick, P. J. (2005). Trends in adult renal replacement therapy in the UK: 1982–2002. QJM: An International Journal of Medicine, 98(1), 21-28. DOI: 10.1093/qjmed/hci007

Wild, S. H., & Byrne, C. D. (2004). Evidence for fetal programming of obesity with a focus on putative mechanisms. Nutrition Research Reviews, 17(2), 153-162. DOI: 10.1079/NRR200487

Neal, D. A. J., Brown, M. J., Wilkinson, I. B., Byrne, C. D., & Alexander, G. J. M. (2004). Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation 1. Transplantation, 77(5), 748-750.

Zhang, J., Phillips, D. I. W., Wang, C., & Byrne, C. D. (2004). Human skeletal muscle PPAR? expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity. American Journal of Physiology: Endocrinology and Metabolism, 286(2), E168-E175. DOI: 10.1152/ajpendo.00232.2003

Neal, D. A. J., Tom, B. D. M., Luan, J., Wareham, N. J., Gimson, A. E. S., Delriviere, L. D., ... Alexander, G. J. M. (2004). Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation, 77(1), 93-99.

Byrne, C. D. (2004). Role of fibrates in reducing coronary risk: a UK Consensus. Current Medical Research and Opinion, 20(2), 241-247. DOI: 10.1185/030079903125002892

Holt, R. I. G., Peveler, R. C., & Byrne, C. D. (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine, 21(6), 515-523. DOI: 10.1111/j.1464-5491.2004.01199.x

Byrne, C. D. (2004). Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 6(4), 308-309. DOI: 10.1111/j.1463-1326.2004.00341.x

Wild, S., & Byrne, C. D. (2004). The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes. Diabetic Medicine, 21(Suppl 4), 8-11. DOI: 10.1111/j.1464-5491.2004.1424-5.x

Byrne, C. D., Holt, H. B., Phillips, D. I. W., Wood, P. J., Zhang, J., & Darekar, A. A. (2004). Which features of the metabolic syndrome predict fatty liver in obese men? Diabetologia, 47, p.A224.

Englyst, N. A., Taube, J. M., Aitman, T. J., Baglin, T. P., & Byrne, C. D. (2003). A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes, 52(5), 1248-1255. DOI: 10.2337/diabetes.52.5.1248

Feher, M. D., Langley-Hawthorne, C. E., & Byrne, C. D. (2003). Cost-outcome benefits of fibrate therapy in type 2 diabetes. British Journal of Diabetes and Vascular Disease, 3(2), 124-130.

Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schacter, M., Cramb, R., Simpson, W. G., & Byrne, C. B. (2003). Statin-fibrate combination therapy for hyperlipidemia: a review. Current Medical Research and Opinion, 19(3), 155-168. DOI: 10.1185/030079903125001668

Holt, R. I. G., & Byrne, C. D. (2003). The clinical implications of the Heart Protection Study. Cardiovascular Risk Abstracts, 1, 5-7.

Waterworth, D. M., Talmud, P. J., Luan, J., Flavell, D. M., Byrne, C. D., Humphries, S. E., & Wareham, N. J. (2003). Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochimica et Biophysica Acta, 1637(3), 200-206. DOI: 10.1016/S0925-4439(03)00021-8

Zhang, J., Day, I. N. M., & Byrne, C. D. (2002). A novel medium throughput quantitative competitive PCR technology to simultaneously measure mRNA levels from multiple genes. Nucleic Acids Research, 30(5), e20-[10pp]. DOI: 10.1093/nar/30.5.e20

Whorwood, C. B., Donovan, S. J., Flanagan, D., Phillips, D. I. W., & Byrne, C. D. (2002). Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes, 51(4), 1066-1075. DOI: 10.2337/diabetes.51.4.1066

Holt, R. I., & Byrne, C. D. (2002). Intrauterine growth, the vascular system, and the metabolic syndrome. Seminars in Vascular Medicine, 2(1), 33-43. DOI: 10.1055/s-2002-23094

Little, P., & Byrne, C. D. (2001). Abdominal obesity and the "hypertriglyceridaemic waist" phenotype. It's probably not yet time to implement screening. BMJ, 322(7288), 687-689. DOI: 10.1136/bmj.322.7288.687

Maison, P., Byrne, C. D., Hales, C. N., Day, N. E., & Wareham, N. J. (2001). Do different dimensions of the metabolic syndrome change together over time?. Evidence supporting obesity as the central feature. Diabetes Care, 24(10), 1758-1763.

Lewis, R. M., James, L. A., Zhang, J., Byrne, C. D., & Hales, C. N. (2001). Effects of maternal iron restriction in the rat on hypoxia-induced gene expression and fetal metabolite levels. British Journal of Nutrition, 85(2), 193-201.

Wild, S. H., & Byrne, C. D. (2001). Prevention of type 2 diabetes and associated cardiovascular disease. Cardiabetes, 1, 20-25.

Byrne, C. D. (2001). Programming other hormones that affect insulin. British Medical Bulletin, 60(1), 153-171.

Grainger, D. J., McWilliam, N. A., Baglin, T. P., & Byrne, C. D. (2001). Suppressing thrombin generation is compatible with the development of atherosclerosis in mice. Thrombosis Research, 102(1), 71-80. DOI: 10.1016/S0049-3848(01)00211-0

Wild, S. H., & Byrne, C. D. (2001). The benefits of a Mediterranean diet, statins, aspirin and unsaturated fats. Thrombus, 5(2), 9-11.

Talmud, P. J., Palmen, J., Luan, J., Flavell, D., Byrne, C. D., Waterworth, D. M., & Wareham, N. J. (2001). Variation in the promoter of the human hormone sensitive lipase gene shows gender specific effects on insulin and lipid levels: results from the Ely study. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1537(3), 239-244. DOI: 10.1016/S0925-4439(01)00076-X

Letter/Editorial

Nobili, V., Mosca, A., Scorletti, E., & Byrne, C. (2017). Reply to: Fructose, uric acid and zonal differences in NASH. Journal of Hepatology. DOI: 10.1016/j.jhep.2017.06.031

Books

Byrne, C. D., & Wild, S. H. (Eds.) (2011). The metabolic syndrome: science and clinical practice. Chichester, GB: Wiley-Blackwell.

Byrne, C. D., & Wild, S. H. (Eds.) (2007). The metabolic syndrome and primary care. Chichester, UK: John Wiley.

Byrne, C. D., & Wild, S. (Eds.) (2005). The metabolic syndrome. Chichester, GB: Wiley.

Book Chapters

Wainwright, P., Ryan, A., Olufadi, R., & Byrne, C. D. (2015). Cholesterol metabolism and vascular disease. In eLS. (pp. 1-12). Chichester, UK: John Wiley. DOI: 10.1002/9780470015902.a0002264.pub3

Wild, S. H., & Byrne, C. D. (2011). The epidemiology of the metabolic syndrome and its association with diabetes, cardiovascular disease and other conditions. In The Metabolic Syndrome. (pp. 1-18). Chichester, GB: Wiley-Blackwell.

Ahmed, M. H., Olufadi, R., & Byrne, C. D. (2010). Metabolic syndrome, diabetes and cardiovascular risk. In P. P. Toth (Ed.), The Year in Lipid Disorders. (pp. 24-45). Oxford, GB: Clinical Publishing.

Olufadi, R., Wild, S. H., & Byrne, C. D. (2009). Cholesterol metabolism and vascular disease. In eLS. Chichester, GB: John Wiley. DOI: 10.1002/9780470015902.a0002264.pub2

Byrne, C. D., & Phillips, D. I. W. (2006). The developmental environment and its role in the metabolic syndrome. In P. Gluckman, & M. Hanson (Eds.), Developmental Origins of Health and Disease. (pp. 265-274). Cambridge, UK: Cambridge University Press.

Ahmed, M. H., & Byrne, C. D. (2005). Non-alcoholic steatohepatitis. In C. D. Byrne, & S. Wild (Eds.), The Metabolic Syndrome. (pp. 279-305). Chichester, GB: Wiley.

Wild, S. H., & Byrne, C. D. (2005). The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In C. D. Byrne, & S. H. Wild (Eds.), The Metabolic Syndrome. (pp. 1-43). John Wiley & Sons Ltd.

Krentz, A. J., Olufadi, R., & Byrne, C. D. (2004). Point-of-care testing in diabetes mellitus. In Point-of-Care Testing. (pp. 309-323). Washington, US: AACC Press.

Byrne, C. D. (2001). Reducing risk of atherosclerotic vascular disease in the diabetic population. In P. Weissberg (Ed.), Horizons in Medicine. (pp. 39-55). Royal College of Physicians.

Conferences

Valletta, J. J., Chipperfield, A. J., & Byrne, C. D. (2009). Gaussian process modelling of blood glucose response to free-living physical activity data in people with type 1 diabetes. In Proceedings of the 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society. (pp. 4913-4916). New York, USA: Institute of Electrical and Electronics Engineers.

Bruce, K. D., Byrne, C. D., & Friedland, J. S. (2009). Metabolic syndrome. In Horizons in Medicine 21: The Proceedings of the Advanced Medicine Conference 2009. (pp. 39-46). (Horizons in Medicine; Vol. 21). London, GB: Royal College of Physicans.

Byrne, C. D., Turzyniecka, M., Wild, S. H., Krentz, A. J., Chipperfield, A. J., Gamble, J., & Clough, G. F. (2009). Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in non-diabetic subjects with central obesity. Paper presented at 45th Annual Meeting of the European Assocation for the Study of Diabetes, .

Englyst, N. A., Kwan, J., Horsfield, G., Bryant, T., & Gawne-Cain, M. (2007). Infection and IL-6 are independent risk factors for a poor functional outcome from ischemic stroke. In European Stroke Conference (Supplement Issue: Cerebrovascular Diseases 2007, Vol. 23, Suppl. 2 ). (pp. p.64). Basel, Switzerland: Karger. DOI: 10.1159/000103854

Professor Byrne gives regular lectures to physicians and students on diabetes, the metabolic syndrome, and the diagnosis and management of hyperlipidaemias.

Pastoral tutor: University of Southampton medical students
Teaching 2nd year Endocrine course University of Southampton Medical students
Teaching 3rd year Endocrinology University of Southampton Medical students
Teaching 3rd year BSc course in Nutrition, University of Southampton students
Teaching ‘Scientific basis of Diabetes’ symposium for Year 3 Medical students
Head of Field Year 3 Research Project BMedSci/MMedSci Diabetes & Endocrinology
Principal lecturer BM Final Year Diabetes Revision
Clinical Supervisor SpRs in Chemical Pathology/Metabolic Medicine
Southampton University Hospitals Trust Course organiser SpR Metabolic Medicine, Southampton University Hospitals Trust
Academic Supervisor: Academic Clinical Fellow Metabolic Medicine 2013 –

Professor Christopher Byrne
Phone: (023) 8120 8818 PA: (023) 8120 5006 Fax: (023) 8120 4221 Email: c.d.byrne@southampton.ac.uk, Room Number: SGH//MP887

Room Number:SGH//MP887

Share this profile Facebook Google+ Twitter Weibo

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.